Scientific Staff

Ruchi Bansal

D:\Ruchi_CV_letters\picture_ruchi.jpg
Dr. Ruchi Bansal
Assistant Professor
Biomaterials Science and Technology- Targeted Therapeutics
MIRA Institute for Biomedical Technology and Technical Medicine
Room no. ZH248
7500AE, Enschede
The Netherlands
Phone: +31534893115
Email: r.bansal@utwente.nl

BIOGRAPHY

Ruchi Bansal obtained her PhD in Pharmacokinetics and Targeting from the University of Groningen. She carried out her PhD project on designing new strategies to target interferon gamma and its signaling domain to the target cells in chronic diseases (liver fibrosis and Cancer). During the last stages of her PhD, she received two prestigious grants Sheila Sherlock research fellowship (from European association for the study of liver diseases, EASL) and The Ruth and Richard Julin’s Foundation Swedish research grant for postdoctoral research at Karolinska Institute, Stockholm, Sweden. From 1st October 2012, she started as postdoctoral researcher at the Department of Biomaterials, Science and Technology, section - Targeted Therapeutics, MIRA Institute of Biomedical Technology and Technical Medicine at University of Twente. In 2014, She received prestigious VENI grant (from NWO, ZonMW) to pursue her research on the development of novel targeted nanomedicines for the treatment of liver diseases. Recently, she received Gastrostart Grant from The Netherlands Society of Gastroenterology (NVGE) to explore “Secreted exosomes (and/or exosomal microRNAs) as biomarkers and therapeutic targets in liver fibrosis, inflammatory diseases and liver carcinoma. Currently, She is an assistant professor in Biomaterials Science and Technology group, where she has independently established her liver research.

RESEARCH INTERESTS

Her research goal is to design and develop targeted nanotherapeutics for the resolution of liver diseases (fibrosis and carcinoma). The main focus of her research is to target different key cell types e.g. myofibroblasts and inflammatory macrophages. She is also actively working on identifying new biomarkers and therapeutic markers for the diagnosis/treatment. The following are the major areas:

  • Designing of macrophage and fibroblasts specific targeting strategies
  • Therapeutic targeting of key signaling pathways e.g. Wnt, Notch and Hedgehog signaling pathways.
  • Identifying new biomarkers (exosomal microRNA) for early diagnosis.
  • Developing ex vivo model systems (e.g. spheroids, liver-on-chip) for efficacy and toxicity studies.
  • Preclinical animal studies for investigation of therapeutic efficacy and imaging of designed nanotheranostics.
  • Developing research: Nano-targeting inflammation: developing and designing theranostic approaches.

Approach: Designing of nanoparticles, assessment of designed novel nanoparticles in developed in vitro and ex vivo model systems, investigation in pre-clinical animal studies with the vision to translate to the patients in clinics.

RESEARCH PROJECTS: Supervisor

  1. Targeted Nanobiologicals for fibrosis and cancer (PhD student: Deby Mardhian, co-supervised by Dr. Jai Prakash)
  2. Nano-therapeutics for the targeted modulation of inflammatory macrophages in liver fibrosis (Dhadhang Kurniawan, co-supervised by Dr. Jai Prakash)
  3. Relaxin-conjugated magnetic nanoparticles as theranostic approach for liver fibrosis (Beata Nagórniewicz, Master student).
  4. Nano-targeting to inflammatory macrophages for the treatment of liver fibrosis (Mikolaj Szachniewicz, Master student).
  5. To study the effect of kinase inhibitors in liver fibrosis (Büsra Öztürk, Master student).
  6. Development of in vivo mimic 3D tumor spheroid model (Ilse Veerbeek, Master Student).

PHD STUDENTS:

  1. Dhadhang Kurniawan (since 2016)
  2. Deby Mardhian (since 2016)

AWARDS AND HONORS

  • Young Investigator Travel award (€1000), United European Gastroenterology week, Oct 2016, Vienna, Austria.
  • Research highlighted in NVH liver magazine http://www.hepatologie.org/files/LEVER%203_15.pdf).
  • EASL Young Investigator award, EASL The International Liver Congress, 2016, Barcelona, Spain.
  • Young Investigator Travel award (€1000), United European Gastroenterology week, Oct 2015, Barcelona, Spain.
  • Junior scholar award for attending Viral Hepatitis Congress (VHC), 2015, Frankfurt, Germany.
  • Young Investigator Travel award (€1000), United European Gastroenterology week, Oct 2014, Vienna, Austria.
  • EASL Young Investigator award (€650), EASL The International Liver Congress, 2013, Amsterdam, Netherlands.
  • AASLD Presidential Poster of Distinction. American association for study for liver diseases (AASLD) Liver meeting 2011 at San Francisco, USA, November 2011.
  • EASL Young Investigator award (€650), EASL monothematic conference, 2011, Petersburg, Germany.
  • EASL Young Investigator award (€650), EASL The International Liver Congress, 2011, Berlin, Germany.
  • Selected for Federation of Innovative Drug Research (FIGON) National PhD competition.
  • 2nd Best Poster Presentation award (€500) at FIGON Dutch Medicine Days, Netherlands.
  • EASL Young Investigator award (€650), EASL The International Liver Congress, 2010, Vienna, Austria.
  • Young Investigator travel Grant from Department of Biotechnology (DBT), Ministry of Science and technology, India, 12th ISVHLD, 2006, Paris, France.

GRANTS

  • 2016-2017 Gastrostart Grant from The Netherlands Society of Gastroenterology (NVGE).
  • 2014-2017 VENI Innovation grant from The Netherlands Organization for Scientific Research (NWO).
  • 2012-2013 The Ruth and Richard Julin’s Foundation Swedish research grant.
  • 2011-2012 Sheila Sherlock Research Fellowship, European association for the study of liver diseases (EASL).
  • 2007-2011 Ubbo Emmius International fellowship for PhD at the University of Groningen, The Netherlands.
  • 2002-2007 Council of Scientific and Industrial Research (CSIR) research fellowship, Delhi, India.
  • 1997-2000 IndusInd fellowship from IndusInd Foundation, India for the University Education.

PUBLICATIONS

Submitted/under review:

  • Akcora BO, Storm G, Bansal R*. Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12 (submitted).
  • Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song W, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J. (2017) Integrin in regulation of myofibroblasts phenotype: Implication for fibrotic diseases. (under review).
  • Yazdani S, Bansal R, Prakash J. (2017) Myofibroblasts targeting to address fibrosis and cancer (under review).
  • Published/accepted:
  • Akcora BO, Storm G, Prakash J, Bansal R*. Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Scientific Reports 2017 Mar 14; 7: 44545. doi: 10.1038/srep44545. Corresponding author
  • Bansal R*, Nagórniewicz B, Prakash J. Clinical advancements in the targeted therapies against liver fibrosis. Mediators of Inflammation. 2016; 2016:7629724. doi: 10.1155/2016/7629724. Review. Corresponding author
  • Berg van den PJ*, Bansal R*, Daoudi K, Steenbergen W, Prakash J. Preclinical detection of liver fibrosis using dual-modality photoacoustic/ultrasound system. Biomedical Optics Express Biomed Opt Express. 2016; 7(12): 5081–5091. *shared authorship. Corresponding author
  • Poosti F, Bansal R, Yazdani S, Prakash J, Beljaars L, van den Born J, de Borst MH, van Goor H, Hillebrands JL, Poelstra K. Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice. Oncotarget. 2016; 7(34): 54240-54252. doi: 10.18632/oncotarget.11095.
  • Chen M, Jagya N, Bansal R, Frelin L, Sällberg M. Prospects and progress of DNA vaccines for treating hepatitis B. Expert Rev Vaccines. 2016 Jan 28:1-12.
  • Bansal R*, Baarlen J van, Storm G, Prakash J. The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific Reports 2015; 5, 18272; doi: 10.1038/srep18272 (2015).*Corresponding author
  • Bansal R*, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M. Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. PLoS One. 2015; 10(6):e0128466. *Corresponding author
  • Hu Q, Rijcken CJ, Bansal R, Hennink WE, Storm G, Prakash J. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials. 2015; 53:370-8.
  • Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Klok P, Van den Born J, de Borst MH, Van Goor H, Poelstra K, Hillebrands JH. Selective delivery of interferon gamma to renal interstitial myofibroblasts: A novel strategy for the treatment of renal fibrosis. FASEB J. 2015; 29(3):1029-42.
  • Bansal R*, Prakash J, de Ruiter M, Beljaars L, Poelstra K. Targeting of Interferon gamma peptidomimetic to disease-inducing cells inhibits liver fibrogenesis and tumor angiogenesis. Journal of controlled release 2014; 179; 18-24.*Corresponding author
  • Bansal R*, Prakash J, de Ruiter M, Poelstra K. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in-vivo. PLoS One. 2014;9(2):e89878. *Corresponding author
  • Bansal R, Tomar T, Ostman A, Poelstra K, Prakash J. Selective targeting of Interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Molecular Cancer Therapeutics 2012; 11(11): 2419-28
  • Bansal R*, Prakash J, de Ruiter M, Beljaars L, Poelstra K. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Molecular Pharmaceutics 2011; 8 (5): 1899-1909. *Corresponding author
  • Bansal R, Post E, Proost JH, de Jager-Krikken Alie, Poelstra K, Prakash J. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis. Journal of Controlled Release 2011; 154 (3): 233-240
  • Bansal R*, Prakash J, Post E, Beljaars L, Schuppan D, Poelstra K. Novel engineered targeted Interferon gamma blocks hepatic fibrogenesis in mice. Hepatology 2011; 54(2): 586-96. *Corresponding author. “Research highlight” published in Nature Reviews Gastroenterology and Hepatology, 2011; 8(7): 359 (IF 2014: 12.61). Highlighted as “key scientific article” in Global Medical Discovery.
  • Prakash J, Bansal R, Post E, de Jager-Krikken A, de Hooge, MH, Poelstra K. Albumin-binding and tumor vasculature determine the anti-tumor effect of 15-deoxy-delta12, 14-Prostaglandin-J2 in vivo. Neoplasia. 2009; 11(12): 1348-58.
  • Gupta P, Tayal R, Durgapal H, Rath S, Acharya SK, Panda SK. Development of highly sensitive Bicistronic vector based non-radioactive antigen-specific cytotoxicity assay. Journal of Immunological Methods 2009; 349(1-2): 28-37.
  • Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004; 127(5): 1356-71.

PATENT

Bansal R, Poelstra K, Beljaars L, Prakash J. Interferon-gamma analogues for the treatment of liver fibrosis. European patent application (EP 09181049.9); US application (US 61/302973) and PCT application (PCT/NL2010/050897).

OTHER ACADEMIC ACTIVITIES:

  • Editorial board member: Scientific reports.
  • Teaching and Supervision: Bachelors and Masters research project supervision; Teaching and coordination of master course “Controlled Gene and Drug Delivery”.
  • Memberships: Member of the European Association for the study of the liver (EASL), Switzerland and Member of Nederlandse Vereniging voor Hepatologie (Dutch society of Hepatology), The Netherlands.
  • Other Editorial Activities: Reviewer for journals such as Scientific reports, PLOS One, Journal of Controlled Release, molecular pharmaceutics etc.
  • Reviewer for grant applications: MRC Medical Research Council, UK; ANR French National Research Agency.